Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy

Completed · Phase 2 · Has a placebo group

Conditions studied: Epilepsy, Focal Seizures, Partial Seizures

In brief

The primary efficacy objective of the study is to determine if adjunctive therapy of natalizumab 300 mg intravenous (IV) every 4 weeks reduces the frequency of seizures in adult participants with drug-resistant focal epilepsy. The secondary efficacy objective is to assess the effects of natalizumab versus placebo in drug-resistant focal epilepsy on additional measures of seizure frequency.

Key facts

Study ID
NCT03283371
Run by
Biogen
People needed
67
Starts
2018-03-20
Expected to finish
2020-11-18
Last updated by the study team
2021-12-14

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.